Russian Heart Failure Journal 2008year Use of the NT-proBNP marker in monitoring of perioperative heart failure in oncological patients with ischemic heart disease

To access this material please log in or register

Register Authorize

Use of the NT-proBNP marker in monitoring of perioperative heart failure in oncological patients with ischemic heart disease

Shestopalova I. M., Gerasimov S. S., Kadagidze Z. G., Shelepova V. M.



Urgency. Monitoring of perioperative heart failure (HF) in patients with IHD is needed for timely detection of patients with early cardiac disorders, silent heart failure (SHF) and cardiovascular complications. Aim. To compare the value of NT-proBNP marker vs. conventional methods for detection of CHF in oncological surgery; to establish threshold NT-proBNP values for prediction of postoperative cardiovascular complications and their outcomes. Materials and methods. Comparative evaluation of HF detection using conventional methods (echoCG; 6-min test; clinical condition scale (CCS)) and the NT-proBNP marker was performed using results of examination prior to a surgery and at 10-14 days of the postoperative period in 45 patients who underwent a radical surgery for lung (n=22), oesophagus (n=8), stomach (n=11), and large or small intestine cancer (n=4). The evaluated group was characterized by prognostically unfavorable IHD including signs of CHF associated with a considerable probability of postoperative cardiovascular complications. Results. Severity of CHF increased in 43 (95.6 %) patients. Sensitivity of conventional methods for detection of postoperative HF signs was 13.3 % for CCS, 22,3 % for echoCG and 73.3 % for the 6-min test. Sensitivity of the NT-proBNP marker corresponded to 95.6 %, which supported a high diagnostic value of the immunoenzyme assay. Preoperative NT-proBNP levels of 152.0 ± 27.3 pg/ml, 318.2 ± 162.4 pg/ml by Elecsys proBNP (Roche) reflect prediction of uncomplicated course of the postoperative period, risk of cardiovascular complications, and high risk of complications with a high probability of fatal outcomes, respectively. Postoperative NT-proBNP marker values of 700.7 ± 396.4 pg/ml reflect severity of thoraco-abdominal surgical interventions without cardiovascular complications; values of 1953.4 ± 276.3 pg/ml reflect the onset of ACS; values of 4839.6 ± 409.7 pg/ml reflect extremely unfavorable (fatal) prognosis of developed complications.
    1.    Burnett J, Kao P, Hu D et al. Atrial natriuretic peptid elevation in congestive heart failure in the human. Science. 1986;231 (4742):1145–1147.
    2.    de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362 (9380):316–322.
    3.    de Lemos JA, Morrow DA, Bentley JH. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345 (14):1014–1021.
    4.    McDonagh T, Robb S, Murdoch D et al. Biochemical detection of left ventricular systolic dysfunction. Lancet. 1998;351 (9095):9–13.
    5.    Murdoch D, McDonagh T, Byrne J et al. Titration of vasodilator therapy in chronic heart failure acording to plasma brain natriuretic peptide concentration: randomized comparison of the hemodinamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138 (6 Pt 1):1126–1132.
    6.    Troughton R, Frampton C, Yandle T et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355 (9210):1126–1130.
    7.    Cardarelli R, Lumicao TG Jr. B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract. 2003 Jul-Aug;16 (4):327–33.
    8.    Wu AH, Packer M, Smith A et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: multisite study. Clin Chem. 2004;50 (5):867–873.
    9.    Бугримова М. А., Савина Н. М., Ваниева О. С. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности. Кардиология. 2006;46 (1):51–64.
    10.    Doust JA, Glasziou PP, Pietrzak E. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004;164 (18):1978–1984.
    11.    de Filippi C, Maynard S, Dunston R. Concomitant Kidney Disease and Heart Failure: Diagnostic and Prognostic Utility of Nterminal proBNP and B-type Natriuretic Peptide. AHA 2005. – abstract 2828. – C160.
    12.    Richards M. The natriuretic peptides in heart failure. Basic Res Cardiol. 2004;99 (2):94–100.
    13.    Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26 (11):1115–1140.
    14.    Park SH, Shub C, Nobrega TP et al. Two dimenshional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiograph correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr. 1996;9 (2):119–128.
    15.    proBNP. Elecsys Systems 1010 / 2010 / Modular analitics E170 [product insent]. Roche Diagnostics 2001.
    16.    Collins SP. Use of Nt-proBNP in the emergency derpartment evaluation of shortness of breath: implications for clinical practice. Emergency Medicine Cardiac research and education group. 2005;6:11–22.
    17.    Januzzi JL, Camargo CA, Baggish AL et al. The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol. 2005;95 (8):948–954.
    18.    Januzzi JL Jr. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med. 2006;73 (2):149–152, 155–157.

To access this material please log in or register

Register Authorize
Ru En